Proteomics Focusing on Immune Markers in Psoriatic Arthritis

Căruntu, Constantin; Boda, Daniel; Dumitrascu, Georgiana Roxana; Constantin, Carolina; Neagu, Monica

doi:10.2217/bmm.14.76

Cited by 45 publications

(41 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is very well documented that DNA has the necessary information to synthesize the whole set of proteins that a cell needs to survive. Modifications in signalling pathways induce changes in gene expression and the result is the alteration in protein levels, which can be objectified through proteomics [25, 26]. In order to understand this mechanism and the way it correlates with different pathologies, clinical proteomics studies the characteristics of a specific protein (quantity, variation in time, and interactions) obtained from various biological fluid or tissue specimens.…”

Section: Introductionmentioning

confidence: 99%

From Normal Skin to Squamous Cell Carcinoma: A Quest for Novel Biomarkers

et al. 2016

Self Cite

View full text Add to dashboard Cite

Squamous cells carcinoma (SCC) is the second most frequent of the keratinocyte-derived malignancies after basal cell carcinoma and is associated with a significant psychosocial and economic burden for both the patient himself and society. Reported risk factors for the malignant transformation of keratinocytes and development of SCC include ultraviolet light exposure, followed by chronic scarring and inflammation, exposure to chemical compounds (arsenic, insecticides, and pesticides), and immune-suppression. Despite various available treatment methods and recent advances in noninvasive or minimal invasive diagnostic techniques, the risk recurrence and metastasis are far from being negligible, even in patients with negative histological margins and lymph nodes. Analyzing normal, dysplastic, and malignant keratinocyte proteome holds special promise for novel biomarker discovery in SCC that could be used in the future for early detection, risk assessment, tumor monitoring, and development of targeted therapeutic strategies.

show abstract

Section: Introductionmentioning

confidence: 99%

From Normal Skin to Squamous Cell Carcinoma: A Quest for Novel Biomarkers

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…For the patients with psoriatic arthritis, the heterogeneity and complexity of psoriatic arthritis pathogenesis requests complex methodological approaches. Going deeper in the pathogenesis of this disease, the associated genetic predisposition can lead to new immune biomarkers whether from the proteomic or genomic area and identify new therapeutic approaches (25).…”

Section: Discussionmentioning

confidence: 99%

Therapeutic management with biological anti-TNF-α agent in severe psoriasis associated with chronic hepatitis B: A case report

Raducan¹,

Bucur

Căruntu³

et al. 2019

Exp Ther Med

Self Cite

View full text Add to dashboard Cite

Systemic therapy in patients with concurrent psoriasis and chronic hepatitis B is a challenging task for both dermatologists and gastroenterologists since there is a high risk for hepatitis B virus (HBV) reactivation and hepatic toxicity under biological therapy. The therapeutic management of a patient with psoriasis and infection with the HBV is a challenge as the classical systemic treatment (methotrexate, acitretin, cyclosporine) shows a high risk of immunosuppression and/or hepatic toxicity and the biological therapy is endangered by the possibility of HBV reactivation. We present the case of a patient with moderate-severe psoriasis and chronic hepatitis B for whom we assessed the risk-benefit relation and considered useful to initiate the anti-TNF therapy concomitantly with the antiviral therapy with entecavir. The therapeutic algorithm included initiation of anti-TNF therapy with etanercept 2x50 mg/week combined with entecavir, an antiviral treatment administered continuously since the diagnosis of the HBV hepatitis, with hepatic function and viral load monitoring. After 3 months of therapy with etanercept the patient was given a dose of etanercept of 50 mg/week combined with entecavir 0.5 mg/day which he continued until week 36 when psoriatic lesions had cleared (PASI=0.6; DLQI=0). No adverse effects were registered and there was no evidence of HBV viral replication or changes in viral markers. We wish to emphasize that the use of etanercept in a patient with psoriasis and hepatitis B is a successful therapeutic alternative which may be safely used concomitantly with entecavir, with regular monitoring of viral load and hepatic function tests.

show abstract

“…For about 20-30% of the patients, which present moderate-to-severe psoriasis, systemic medication (phototherapy, methotrexate, cyclosporine, acitretin or biologic agents) is mandatory (13,28). Psoriatic arthritis affects between 6-42% of patients and if early treatment is not established, local inflammation will produce joint destruction and disability (50). During the treatment, some patients can experience side effects, relapses or insufficient response (13).…”

Section: Therapy Against Il-17mentioning

confidence: 99%

Psoriasis: Association of interleukin-17 gene polymorphisms with severity and response to treatment (Review)

et al. 2019

View full text Add to dashboard Cite

Psoriasis is a chronic, inflammatory disease with a complex pathogenesis that is not yet fully understood. Although it is a multifactorial disease, the genetic factor has a major role in the pathogenesis of psoriasis. Genome wide association studies have identified over 50 genetic loci associated with psoriasis risk. Beside TNF-α or IL-23, the IL-17 family is a newer group that has proven implications in the pathogenesis of psoriasis. The most important members of the family, with pro-inflammatory qualities, are IL-17A and IL-17F. These interleukins are produced by a varied number of cells, but by far the most important are Th17 cells. Of the patients 20-30% present moderate-to-severe psoriasis, therefore, systemic medication (phototherapy, methotrexate, cyclosporine, acitretin or biologic agents) is mandatory. The necessity of an individualized treatment plan, for each patient, is imperative in order to establish the best strategy for non-responders to classical treatment or to other biologic treatments. The discovery of Th17 pathway improved the treatment and prognosis of psoriasis. Anti-psoriatic agents against IL-17 or its receptors are a novel group of biologic agents; these include ixekizumab, secukinumab and brodalumab. Polymorphisms of IL-17 family have been correlated with the severity and response to treatment in psoriasis, and also with the risk of inflammatory, infectious, autoimmune or neoplastic pathologies. The significant difference in the presence or absence of susceptibility loci in different population is due to genetic background and environmental factors that have a major impact on disease predisposition. In this study, we reviewed the importance and influence of the IL-17 polymorphisms as predictors of response to treatment and severity of the disease.

show abstract

Proteomics Focusing on Immune Markers in Psoriatic Arthritis

Cited by 45 publications

References 77 publications

From Normal Skin to Squamous Cell Carcinoma: A Quest for Novel Biomarkers

From Normal Skin to Squamous Cell Carcinoma: A Quest for Novel Biomarkers

Therapeutic management with biological anti-TNF-α agent in severe psoriasis associated with chronic hepatitis B: A case report

Psoriasis: Association of interleukin-17 gene polymorphisms with severity and response to treatment (Review)

Contact Info

Product

Resources

About